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Abstract
  
 Mortality in cancer is primarily due to failure of metastasis prevention. One 
strategy to target the cancerous cell is Boron Neutron Captured Therapy which showed 
high affinity toward cancer cells and reported to have anti-proliferative as well as anti-
metastatic activities. Cancer Chemoprevention Research Center Faculty of Pharmacy 
Universitas Gadjah Mada, has developed boron-containing substance namely pentagama-
boronon-0 (PGB-0) which is known to exhibit anticancer activity towards breast cancer 
cell. The purposes of this research are focused to explore the anti-migratory activities 
of PGB-0-So against triple negative breast cancer cell. The MTT cytotoxicity assay of 
PGB-0-So against 4T1 breast cancer cell line were found to exert potential effect in 
dose-dependent manner with IC50 values of 39 µM. The study of cell migration inhibition 
using in vitro wound healing assays and gelatin zymography on highly metastasis breast 
cancer cell line 4T1, following the treatment of sub IC50 doses of PGB-0-So complex 
slightly inhibited cell migration through the inhibition of matrix metalloproteinase-9 
expression. These findings suggest that PGB-0-So is potential as an anticancer agent. 
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INTRODUCTION
 Breast cancer is the most common type of 
cancer causing mortality for women. In 2012, there 
were registered 1.67 million new cases of breast 
cancer mortality in women by 198,000 (Ferlay, 
et al., 2012). It was estimated that approximately 
10-15% of breast cancer was known to be triple 
negative breast cancer (TNBC) (Dawood, 2010). 
This breast cancer subtype is positive-metastatic 
breast cancer (MBC) which have worse prognosis 
leading to aggressive disease. Moreover, failure of 
metastasis prevention primarily caused mortality in 
breast cancer.
The treatment of metastasis in breast cancer was 
conducted by chemotherapy, such as doxorubicin 
which performed strong cytotoxicity against 
cancer cells.  Despite its potent anticancer activity, 
doxorubicin had several limitations for long-term 
use including cardiotoxicity and chemoresistance 
(Carvalho, et al., 2009; Thorn, et al., 2011). 
In addition, low dose of doxorubicin induces 
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epithelial-mesenchymal transition (EMT) leading 
to metastasis on breast cancer cells (MBC) 
(Bandyopadhyay, et al., 2010). Hence, several anti-
metastatic agents had been developed to treat MBC.
  Development of anti-metastatic agents as 
potential candidate of chemotherapeutic agents 
has been established over the years. Patients 
characterized as triple negative breast cancer are 
treated with taxanes or platinum compounds (Gavilá, 
et al., 2015). Similar to doxorubicin, taxanes in 
low dose induced peripheral neuropathy in breast 
cancer (Bhatnagar, et al., 2014), while platinum 
compound (cisplatin) induced EMT in ovarian 
cancer (Baribeau, et al., 2014). Thus, the effective 
anti-metastatic agents need to be developed further.
  Curcumin analogues based on benzylidine 
cyclopentanone backbone such as Pentagamavunon-0 
(PGV-0) and Pentagamavunon-1 (PGV-1) exert 
potent cytotoxic (Meiyanto, et al. (2006); Nurulita, 
et al. (2006); Dai, et al. (2007); Dai, et al. (2011); 
Hermawan, et al. (2011); Meiyanto, et al. (2014) 
and anti-metastatic activities toward several 
types of breast cancer cells (Putri, et al., 2016). 
Pentagamaboronon-0 (PGB-0) is a novel curcumin 
analogue based on benzylidine cyclopentanone 
developed by Faculty of Pharmacy Universitas 
Gadjah Mada. Cytotoxicity of PGB-0 toward HER2 
positive breast cancer had been determined and 
showed to decrease HER2 expression (Utomo, et 
al., 2017). PGB-0 also performed anti-metastatic 
activity toward triple negative breast cancer cells 
(unpublished data). However, similar to curcumin, 
PGB-0 is less soluble in water. To improve solubility 
of PGB-0, we synthesized the complex form of 
PGB-0 with polyol sugar, sorbitol, namely PGB-0-
So. 
 This study aims to develop PGB-0-So as novel 
anti-cancer agent especially through the inhibition 
of cell migration. 4T1 cells were used as a model 
of highly metastatic breast cancer cell line. Possible 
anti-metastasis activities of PGB-0-So were 
analyzed by using scratch wound healing assay and 
gelatin zymography. The result of this study will 
be used for further experiment in order to develop 
novel anti-migratory agents from PGB-0-So.
MATERIALS AND METHODS
Chemicals
 PGB-0-So was synthesized by Cancer 
Chemoprevention Research Center, Faculty of 
Pharmacy, Universitas Gadjah Mada. Doxorubicin 
was purchased from Sigma. 
Cell Culture
 4T1 breast cancer cells were obtained from 
Prof. Masashi Kawaichi, M.D., Ph.D (Nara Institute 
of Science and Technology, NAIST, Japan).  The 
cells were maintained in Dulbecco’s Modified 
Eagles Medium (DMEM) high glucose (Sigma, St. 
Louis, CA, USA) with 10% FBS (Sigma), HEPES, 
sodium bicarbonate, 1000 U/mL of Penicilin-1000 
U/ml of Streptomycin and 0.5 µg/mL Fungizone 
(Gibco, New York, USA).
Scratch Wound Healing Assay
 The 4T1 breast cancer cells were seeded 
7.5x104 cells per well in 24 well-plate.  Cells were 
incubated for 24 hours until 80% confluent.  Media 
was removed and well was washed with 100 µL 
PBS (Sigma).  Then cells were added with media 
contained 0.5% FBS for starvation and incubated 
for 22 hours.  Each well was scratched vertically by 
using yellow tip and treated with Doxorubicin 10 
nM as positive control, PGB-0-F, and combination 
of both compounds. The closures of cell migration 
were observed in 0, 18, 24 and 42 hours under 
inverted microscope (Olympus, Tokyo, Japan) and 
captured by Handphone (Samsung, Seoul, South 
Korea).
Gelatin-Zymography Methods 
 A total of 2 x 105 4T1 cells were planted in 
a 6-well plate with 2 mL of culture medium and 
incubated for 24 hours. The samples solution 
was carried out using culture medium containing 
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0.5% FBS. After incubation, the media is removed 
and washed with PBS 1 mL 1 times. Cell then 
treated with various concentration of PGB-0-So 
and doxorubicin. Estradiol was used to induce 
the expression of MMP-9. The cells then were 
incubated again for 48 hours. Culture medium then 
collected in 1.5 mL microtube and centrifuged at 
4oC and then take the supernatant. The sample has 
been obtained by loading the buffer and running 
in appropriate concentration electrophoresis. 
Gel that has gelatin mold. The checking process 
with electrophoresis (V = 120V, I = 60A) was 
carried out for 130 minutes. After that, the gel is 
done and renaturation using a renaturing solution 
containing Triton-X 100 to remove SDS for 30 
minutes. Continued with incubation for 20 h using 
an incubation solution at 37oC. Then, it should be 
stained with coomasie brilliant blue for 30 minutes, 
and through destaining using a destaining solution 
until the transparent blue band appears.
Data Analysis
 Scratch wound healing analysis was figured 
out by measuring the distance between scratch 
edges using ImageJ software then comparing the 
untreated and treated cells. Data from multiple 
scratch within the same test group were analyzed 
using Analysis of Variance test to analyze the 
difference between experimental group. Data were 
presented as mean ± S.D and analyzed by one-
way ANOVA. p < 0.05 was considered statistically 
significant.
RESULTS AND DISCUSSION
Anti-migratory Effect of PGB-0-So and Its 
Combination with Doxorubicin against 4T1 
cell
 The purpose of this study is to develop a 
novel anti-cancer agent which especially plays 
role in inhibiting cancer cell migration. In this 
study, we used highly metastatic breast cancer cell 
model, 4T1, to explore the potency of PGB-0-So 
in inhibiting cell migration. Low concentration of 
Doxorubicin (Dox) in this study was used to induce 
migration (Bandyopadhyay, et al., 2010). Scratch 
wound healing assay was conducted to observe 
cells migration following the treatment of several 
concentrations under IC50 value of 1/8, 1/4, and 
1/2 of IC50, which are nontoxic and appropriate 
concentration to observe cell migration activity. 
The IC50 value of PGB-0-So against 4T1 cell was 40 
μM. After 42 hours observation, Dox increased the 
% closure up to 100% indicating the cell migration 
activity. On the other hand, single treatment of 
1/2 IC50 PGB-0-So (20 μM) showed significant 
inhibitory activity against 4T1 cell line whereas the 
concentrations of 1/4 and  1/8 IC50 value (10 and 5 
μM) of PGB-0-So showed unsignificant inhibitory 
anti-migratory activity compared to the untreated 
group. Interestingly, combination of Dox with all 
concentrations of PGB-0-So showed significant 
anti-migratory activity against doxorubicin-induced 
4T1 cell (Figure 1). The result needs to be confirmed 
with the expression of certain protein played role on 
cells migration or invasion.
Effect of PGB-0-So and Its Combination with 
Doxorubicin against MMP-9 Expression
 Secondary Cancer cells migration and invasion 
was tightly regulated by certain proteins especially 
Matrix Metalloproteinase 9 (MMP-9). Role of 
MMP-9 on cells migration and invasion was to 
degrade extracellular matrix (ECM) around cancer 
cells (Yabluchanskiy, et al., 2013; Reunanen, et 
al., 2013). To observe possible effect of PGB-0-So 
on the decreasing expression of MMP-9, gelatine 
zymography was performed. Low concentration 
of Dox (10 nM) showed decreased expression 
of MMP-9 expression indicating the different 
possible effector of anti-migratory activity might 
be induced by Dox. Amalina, et al. (2017) reported 
that low dose of Dox induced EMT through Rac1 
independent-lamellipodia formation by which 
the initial progression of cancer cell migration. In 
contrast, both single treatment of PGB-0-So and 
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Figure 1. Anti-migratory Effect of PGB-0-So against Highly Metastatic, 4T1, Cells Migration. 4T1 cells (7.5x104 
cells/well) were treated with PGB-0-F in the concentration as indicated in the figure, then subjected for 
scratch wound healing assay. A: The morphology of the cells after scratch and treated with PGB-0-So. Ob-
servations were made after 18, 24 and 42 hour of treatment under an inverted microscope with magnification 
of 100x. B: The percentage of 4T1 cells closure after treatment. The area of the scratch were analyzed using 
ImageJ software then % closure was calculated in accordance with the procedures of the analysis (p<0.05).
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its combination with Dox showed the decreasing 
expression of MMP-9 protein in dose dependent 
manner (Figure 2). Hence, anti-migratory effect of 
PGB-0-So against 4T1 cell might be through the 
suppression of MMP-9 expression.
DISCUSSION
 Inhibition of tumor cell migration is crucial 
in the therapy and inhibition of cancer spread, 
especially in metastasis. Thus, it is necessary to 
develop anti-migratory agent to overcome this 
situation.  Previous research showed that PGB-
0 exhibited anti-migratory effect as well as 
inhibited MMP-9 expression (unpublished data). 
MMP-9 is a family member of zinc- and calcium-
dependent endopeptidases, 88 kDa protein which 
has numerous cell activities, involving in various 
Figure 2.  Result of MMP-9 Expression Following The Treatment of PGB-0-So, Doxorubicin, and PGB-0-So Combi-
nation with Doxorubicin (48 hours). A: Clear protein bands formed indicating the presence of MMP-9 protein. 


























































































physiological functions, such as cell-cell contact, 
tissue remodeling cell migration and cellular 
differentiation (Yabluchanskiy, et al., 2013; 
Vandooren, et al., 2013). 
 Other study using boron containing 
compound, phenylboronic acid showed that this 
compound has potency as selective inhibitor of 
cancer cell migration and viability without effecting 
non-tumorigenic cell lines (Bradke, et al., 2008; 
McAuley, et al., 2011).  The main purpose of this 
study is to explore the potential metastasis-inhibitory 
of PGB-0-So on triple negative breast cancer cells, 
4T1.  In this study, 4T1 cells were used as the model 
of human metastatic breast cancer cells because it is 
highly metastatic breast cancer cells. This cells can 
metastasize to liver, lung, bone and brain, making 
it a good model of human metastatic breast cancer 
(Pulaski, et al., 2000; DuPré, et al., 2007).
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 Doxorubicin is usually used as 
chemotherapeutic first-line treatment of several type 
of cancer especially triple negative breast cancer. 
Prolonged use of doxorubicin showed toxicity 
effect such as cardiotoxicity and hepatotoxicity 
(Pedrycz and Kramkowska, 2016).  On the other 
hand, another research reported that doxorubicin 
at low dose can enhanced cancer cell migration 
by inducing lamellipodia formation (Amalina, et 
al., 2017).  Previous studies showed the migration 
inbitory activity of PGB-0-So (Pentagamaboronon-
0-sorbitol) in 4T1 cells (unpublished data). PGB-0-
So showed cytotoxic effect on 4T1 cells with IC50 
values of 39 µM (unpublished data).  While PGB-0 
has IC50 value 300 µM in 4T1 cells (unpublished 
data), and 270 µM in MCF-7/Her2 cells (Utomo, et 
al., 2017).
 In this present study, we also observed the 
inhibition of cancer cell migration as the one of 
parts of metastasis process by treatment of PGB-
0-So through scratch wound healing assay. Cell 
migration is part of the metastasis process. Based 
on the percent graph of 4T1 cell closure (Figure 1A) 
the treatment of PGB-0-So with concentration 5 and 
10 µM had demonstrated unsignificant migration 
inhibitory activity in all time course compared to 
the negative control group (untreated). On the other 
hand, 20 µM concentration of PGB-0-So began to 
affect significantly the inhibition of cell migration 
especially after 42nd hours.
 The treatment of doxorubicin 10 nM 
showed higher % closure than untreated cells, it 
means that doxorubicin induced cell migration. 
Previous study reported that doxorubicin induced 
lamelipodia formation and cell migration in 4T1 
and MCF-7/Her2 cells (Amalina, et al., 2017). 
Furthermore, combination treatment of PGB-0-
So and doxorubicin showed inhibition of 4T1 
cell migration 42 hours after incubation time. At 
this incubation time both single PGB-0-So 1/2 
IC50 treatment and its combination with 10 nM 
doxorubicin showed significant differences with 
the difference in closing percentages compared 
to the control of cells without treatment. Whereas 
when PGB-0-So treatment with doxorubicin 10 nM 
compared with a single treatment doxorubicin 10 
nM resulted in lower closing percentage indicating 
the inhibitory activity of PGB-0-So.
 It has been reported in the breast cancer patients 
where there is a significant association between high 
MMP9 expression and poor survival (Song, et al., 
2013) so that MMP-9 expression would be potential 
therapeutic agents to inhibit development of cancer 
metastasis.  Curcumin analogue PGB-0-So showed 
tendency of inhibitory effect of MMP-9 activity in 
gelatin zymograph assay 48 hours after treatment. 
Previous study also showed that PGB-0 inhibited 
MMP-9 expression (soon will be published). 
Curcumin itself showed the inhibition of MMP-9 
expression by inhibiting Mitogen- activated Protein 
Kinase (MAPK) phosphorylation (Cao, et al., 2014). 
Other research showed that simultaneous silencing 
of MMP-9 in breast cancer cells decreased the 
wound healing, migratory, invasive and adhesive 
capacity of the cells by increasing cell-cell adhesion 
and modulating EMT genes (Moirangthem, et al., 
2016).
CONCLUSION
 PGB-0-So exhibits anti-migration effect 
against doxorubicin treatment cells.  PGB-0-So also 
inhibits MMP-9 activity which has role in tumor 
invasion.
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